Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Artrya.
RELATED STOCKHEAD STORIES
Health & Biotech
The ASX biotechs with secured FDA clearances in 2024, and others looking likely
Health & Biotech
ASX Health Stocks: NSB jumps 30pc after disclosing upcoming meeting with US FDA
Health & Biotech
The next Neuren? These ASX biotech stocks have pending FDA catalysts in 2024
Health & Biotech
ASX biotechs with big catalysts in 2024: Part 2
Health & Biotech
FDA submission looms as Artrya’s AI platform aims to capture the huge cardio diseases market
Health & Biotech
ASX Health Stocks: 4DX jumps 15pc after FDA clearance; while AI-focused biotechs TrivarX and Artrya also gain
News
ASX Quarterly Wrap: Brainchip progresses AI chip commercialisation, RBX grabs tasty James Bay lithium projects
News
In Case You Missed It: A high flying copper stock and a vanadium offtake deal
Health & Biotech
ASX Health Stocks: Proteomics’ blood test PromarkerD effective with diabetes drug Canagliflozin
Health & Biotech
ASX Health Stocks: These three ASX biotechs get to strut their stuff with Bell Potter and Nature Portfolio
News
LAST ORDERS: A mildly seditious look back at what happened here, and there, today
News
ASX Small Caps Lunch Wrap: Who’s reeling from a head knock this morning?
News
Top 10 at 10: Friday’s top (and bottom) ASX stocks in early trade
Stockhead TV
Artrya: A big data approach to the early detection of heart disease
Health & Biotech
ASX Health Stocks: Artrya goes to America while EZZ goes live on TikTok China
News
Market Highlights and 5 ASX Small Caps to watch on Monday
Health & Biotech
